{"id":4307,"date":"2026-06-13T09:13:24","date_gmt":"2026-06-13T16:13:24","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=4307"},"modified":"2026-06-13T09:13:25","modified_gmt":"2026-06-13T16:13:25","slug":"trinomab%ef%bc%9athe-ipo-registration-has-become-effective","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/","title":{"rendered":"Trinomab\uff1aThe IPO registration has become effective."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">According to the official website of the Shanghai Stock Exchange STAR Market, Trinomab&#8217;s IPO registration has become effective, and the company is about to be officially listed on the STAR Market. Trinomab adopted the fifth set of listing standards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Founded in 2015, Trinomab is dedicated to the development, manufacturing, commercialization, and potential replacement of global specific blood products through fully human monoclonal antibody innovations. To date, the company has developed multiple innovative monoclonal antibodies, including one commercialized product.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Trinomab&#8217;s first product, <strong>Siltartoxatug<\/strong> (<strong>TNM002<\/strong>), is a recombinant anti-tetanus toxin monoclonal antibody that neutralizes tetanus toxin to prevent disease onset, indicated for emergency prevention of tetanus after trauma exposure. In February 2025, the drug was approved for marketing in China. Additionally, Trinomab is advancing the registration of <strong>Siltartoxatug<\/strong> in overseas regions including the United States, the European Union, and Indonesia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Another core product, <strong>TNM001<\/strong> Injection, is a fully human monoclonal antibody that provides immunization by targeting the respiratory syncytial virus (RSV) Pre-F protein. Preclinical and clinical data have demonstrated that TNM001 has good efficacy and safety in preventing RSV infection. Currently, the marketing application for TNM001 in non-high-risk and high-risk infant populations was accepted by the CDE in February 2026 and has been granted priority review.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Trinomab&#8217;s other internally developed pipeline products include:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM009<\/strong>&nbsp;is a recombinant anti-nerve growth factor (NGF) fully human monoclonal antibody for analgesia. In March 2023, the CDE approved the clinical trial application for TNM009. The drug has now completed Phase I clinical trials. Trinomab is preparing to conduct a Phase IIa proof-of-concept (POC) trial, TNM009-201, in patients with bone metastasis cancer pain, with the primary objective of preliminarily validating the efficacy and safety of TNM009 in this patient population.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM005<\/strong>&nbsp;is an anti-varicella-zoster virus (VZV) fully human monoclonal antibody, a recombinant anti-VZV monoclonal antibody. In April 2023, the FDA approved the clinical trial application for TNM005 for the indication of post-exposure prophylaxis of VZV in high-risk populations. The drug has now completed Phase I clinical trials in the United States.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM006<\/strong>&nbsp;is an intravenously administered anti-human cytomegalovirus (HCMV) fully human monoclonal antibody. In May 2023, the CDE approved the clinical trial application for TNM006.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM035<\/strong>&nbsp;is a fully human monoclonal antibody that specifically binds to the dengue virus E protein, intended for the prevention and treatment of dengue virus infection. TNM035 is currently in preclinical studies. In November 2025, TNM035 entered the CMC (chemistry, manufacturing, and controls) development phase.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM050<\/strong>&nbsp;is a fully human monoclonal antibody that specifically binds to the rabies virus G protein, intended for post-exposure prophylaxis of rabies virus, currently in preclinical studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>TNM020<\/strong>&nbsp;is a fully human monoclonal antibody that specifically binds to the genital herpes simplex virus gD protein, intended for the prevention and treatment of genital herpes simplex virus infection, currently in preclinical studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to the prospectus, Trinomab&#8217;s main business revenue in 2025 was RMB 51.2249 million, primarily from drug sales of Stedomab after its market launch.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy <strong><strong>TNM009\/<\/strong>TNM001<strong>\/TNM005\/TNM006\/TNM035\/TNM050\/TNM020<\/strong>\u00a0<\/strong>from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to the official website of the Shanghai Stock Exchange STAR Market, Trinomab&#8217;s IPO registration has become effective, and the company is about to be officially listed on the STAR Market. Trinomab adopted the fifth set of listing standards. Founded in 2015, Trinomab is dedicated to the development, manufacturing, commercialization, and potential replacement of global [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4308,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trinomab\uff1aThe IPO registration has become effective. - Xpharma China<\/title>\n<meta name=\"description\" content=\"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab\uff1athe-ipo-registration-has-become-effective\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab\uff1athe-ipo-registration-has-become-effective\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-13T16:13:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-13T16:13:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2343\" \/>\n\t<meta property=\"og:image:height\" content=\"855\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Trinomab\uff1aThe IPO registration has become effective.\",\"datePublished\":\"2026-06-13T16:13:24+00:00\",\"dateModified\":\"2026-06-13T16:13:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/\"},\"wordCount\":531,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/\",\"name\":\"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png\",\"datePublished\":\"2026-06-13T16:13:24+00:00\",\"dateModified\":\"2026-06-13T16:13:25+00:00\",\"description\":\"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png\",\"width\":2343,\"height\":855,\"caption\":\"Trinomab\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trinomab\uff1aThe IPO registration has become effective.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","description":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab\uff1athe-ipo-registration-has-become-effective\/","og_locale":"en_US","og_type":"article","og_title":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","og_description":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab\uff1athe-ipo-registration-has-become-effective\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-13T16:13:24+00:00","article_modified_time":"2026-06-13T16:13:25+00:00","og_image":[{"width":2343,"height":855,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Trinomab\uff1aThe IPO registration has become effective.","datePublished":"2026-06-13T16:13:24+00:00","dateModified":"2026-06-13T16:13:25+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/"},"wordCount":531,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/","name":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png","datePublished":"2026-06-13T16:13:24+00:00","dateModified":"2026-06-13T16:13:25+00:00","description":"Trinomab\uff1aThe IPO registration has become effective. - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/\u5fae\u4fe1\u56fe\u7247_2026-06-14_000631_880.png","width":2343,"height":855,"caption":"Trinomab"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/trinomab%ef%bc%9athe-ipo-registration-has-become-effective\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Trinomab\uff1aThe IPO registration has become effective."}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=4307"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4307\/revisions"}],"predecessor-version":[{"id":4309,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4307\/revisions\/4309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/4308"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=4307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=4307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=4307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}